Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | HTR2C | P28335 | 3/20 | 0.54 |
| ▸ | CNR1 | P21554 | 12/20 | 0.53 |
| ▸ | CNR2 | P34972 | 10/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6104701 | 0.91 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL4508459 | 0.89 | HTR2A (0.54) | HTR2AHTR2CCNR1CNR2SLC6A4 | |
| SCHEMBL675250 | 0.84 | HTR2A (0.74) | HTR2AHTR2CCNR1CNR2SLC6A4 | |
| SCHEMBL6105921 | 0.83 | CNR1 (0.53) | HTR2AHTR2CCNR1CNR2SLC6A4 | |
| SCHEMBL6103715 | 0.82 | CNR1 (0.63) | CNR1CNR2 | |
| SCHEMBL6106013 | 0.81 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL675859 | 0.81 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL6106413 | 0.80 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL4491084 | 0.80 | CNR1 (0.58) | CNR1CNR2 | |
| SCHEMBL4506215 | 0.79 | CNR1 (0.76) | HTR2AHTR2CCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109216-B2 | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-09-19 | — | — | US | disclosed |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | CNR1, CNR2, HRH4 | HTR2A 110/4885HTR2C 66/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.